Health and Healthcare

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

141 Articles

Jon C. Ogg | Mar 25, 2013 at 10:50 AM EDT

The Risk-Reward Case for Sarepta — Stock Going to $19 or $47 by Mid-May

ThinkstockSarepta Therapeutics Inc. (NASDAQ: SRPT) should have received a huge boost from “The Barron’s Effect” on Monday. The financial publication,…

Paul Ausick | Oct 3, 2012 at 4:02 PM EDT

24/7 Wall St. Closing Bell — October 3, 2012: Markets Just Bump Along (MOS, CSCO, MHP, KORS, WPRT, FDO, MON, RPM, MAR, ISCA, HPQ, SRPT, VRNG, GOOG, LEAP, PCS)

The three major U.S. stock indexes opened slightly higher this morning following a refusal by Spain’s prime minister to seek…

Jon C. Ogg | Oct 3, 2012 at 12:53 PM EDT

How Sarepta Got On The Map

Sarepta Therapeutics Inc. (NASDAQ: SRPT) is a company which many biohealth and biotech investors have likely never heard of. At least…

247sam | Oct 3, 2012 at 11:11 AM EDT

Today’s Market Winners and Losers

Photo by Spencer Platt/Getty ImagesThe stock market is up slightly Wednesday, with the Dow Jones Industrial Average up 0.07%, the…

Paul Ausick | Jul 24, 2012 at 4:05 PM EDT

24/7 Wall St. Closing Bell — July 24, 2012: Markets Fall on Weak Quarterly Results

The three major US stock indexes opened roughly flat this morning as Spanish 10-year bond yields rose to 7.5% and…

247sam | Jul 24, 2012 at 11:13 AM EDT

Today’s Market Winners and Losers

Once again, concerns over European debt is sending stocks tumbling. The Dow is down 0.61%, the Nasdaq is down 0.39% and the…

1 … 8 9 10

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

The Risk-Reward Case for Sarepta — Stock Going to $19 or $47 by Mid-May

24/7 Wall St. Closing Bell — October 3, 2012: Markets Just Bump Along (MOS, CSCO, MHP, KORS, WPRT, FDO, MON, RPM, MAR, ISCA, HPQ, SRPT, VRNG, GOOG, LEAP, PCS)

How Sarepta Got On The Map

Today’s Market Winners and Losers

24/7 Wall St. Closing Bell — July 24, 2012: Markets Fall on Weak Quarterly Results

Today’s Market Winners and Losers

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Sarepta Therapeutics : SRPT

All Sarepta Therapeutics Articles

The Risk-Reward Case for Sarepta — Stock Going to $19 or $47 by Mid-May

24/7 Wall St. Closing Bell — October 3, 2012: Markets Just Bump Along (MOS, CSCO, MHP, KORS, WPRT, FDO, MON, RPM, MAR, ISCA, HPQ, SRPT, VRNG, GOOG, LEAP, PCS)

How Sarepta Got On The Map

Today’s Market Winners and Losers

24/7 Wall St. Closing Bell — July 24, 2012: Markets Fall on Weak Quarterly Results

Today’s Market Winners and Losers

UFO ETF Faces a Critical Test: Can Pre-Profit Space Stocks Deliver on $1.85B Backlog

Concentration Risk High as Top Two Stocks Steer U.S. Communication Services ETF Performance

Amazon and Tesla Drive One-Third of FDIS as U.S. Spending Surges Despite Recession-Level Sentiment

Featured Reads

Fed’s Rate Freeze Could Sting for Social Security Recipients

'Convert $100,000 a Year to Get Them to the Top of the 22%': The Roth Plan for a Couple With $2.3M in 401(k)s